Michael Ong

6PUBLICATIONS

66CO-AUTHORS

Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (6)

Sort by Publication Date:

|May 26, 2026

Forecasting Trends in Androgen Deprivation Therapy Intensification for Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Population-Based Cohort and Time-Series Analysis.

|Dec 24, 2025

Canadian Prostate Cancer Trends in the Context of PSA Screening Guideline Changes.

Anna N Wilkinson, Larry F Ellison, Shary X Zhang

|Feb 21, 2025

Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors.

Valentina Gambardella, Michael Ong, Maria E Rodriguez-Ruiz

|Nov 08, 2024

Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer.

Eric Winquist, Sebastien J Hotte, Kim Chi

|Mar 25, 2024

Real-World Evaluation of Primary Versus Secondary Prevention of Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer.

William J Phillips, Fred Saad, Jennifer Leigh

|Nov 05, 2020

OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors.

Martin Gutierrez, Victor Moreno, Kimberley M Heinhuis

Pageof 1

Frequent Collaborators

Scott C Morgan

Aly-Khan Lalani

Martin Gutierrez

Victor Moreno

Anthony J Olszanski

José Trigo

Maria Ochoa de Olza

Stephen Leong

Christopher J D Wallis

1 joint publications

Eric Winquist

Frequent Collaborators

Scott C Morgan

Aly-Khan Lalani

Martin Gutierrez

Victor Moreno